Company profile: Adaptive Phage Therapeutics
1.1 - Company Overview
Company description
- Provider of phage-based therapeutic services for multi-drug resistant pathogenic bacteria, using clinical technology to match phages to patient-specific infections; offerings include BX004 for cystic fibrosis Pseudomonas aeruginosa, BX211 for diabetic foot osteomyelitis, personalized and optimized phage therapies, and the XMarker platform for microbial biomarker discovery.
Products and services
- Personalized Phage Treatment: Custom-engineered therapy that matches phages to patient-specific bacterial infections, tailoring to specific strains to target multi-drug resistant pathogens, developed within 6-8 weeks
- Optimized Phage Therapy: Population-scale phage therapy architected for broad patient populations, targeting bacterial host range and resistance, produced within 1-2 years to address multi-drug resistant infections
- BX004: Clinical-grade phage therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa respiratory infections, engineered to improve pulmonary function and reduce lung infections
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Adaptive Phage Therapeutics
Axial Therapeutics
HQ: United States
Website
- Description: Provider of gut-restricted and gut-selective small molecule therapeutics targeting the microbiome–gut–brain axis for neurological diseases. Offerings include AB-2004, a Phase 2 therapy for irritability associated with autism that adsorbs gut bacterial metabolites, and AX-5006 for Parkinson’s. Also offers a Microbial-Inspired Therapeutics discovery platform and early-stage programs in liver disease and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axial Therapeutics company profile →
Solarea Bio
HQ: United States
Website
- Description: Provider of microbial therapeutics and microbial-based solutions targeting chronic inflammation. Develops Defined Microbial Assemblage products combining probiotic microbes from fruits and vegetables with prebiotic fibers, advances medical foods, and creates synbiotics to protect against bone loss. Also offers licensing of its microbial-based technology, including a technology licensing agreement with ADM.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Solarea Bio company profile →
Seres Therapeutics
HQ: United States
Website
- Description: Provider of microbiome therapeutics, including VOWST, an FDA-approved oral microbiota-based therapy to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment; SER-155, an investigational oral microbiome therapeutic aimed at reducing gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients; and a platform to design, test, and manufacture bacterial consortia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seres Therapeutics company profile →
TargEDys
HQ: France
Website
- Description: Provider of functional and medical foods and medical products that harness the microbiota and hormone-mimetic proteins to regulate appetite and treat eating disorders such as hyperphagia and anorexia. Portfolio includes Hafnia alvei HA4597 and LpWJL precision probiotics, PreciBiomic oxytocin-mimetic strains for stress/anxiety, and Symbiosys Satylia distributed by Biocodex in select European countries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TargEDys company profile →
Xycrobe
HQ: United States
Website
- Description: Provider of early-stage biotechnology research and development leveraging extensive human microbiome data to develop novel therapies for clinical applications, with innovations that utilize microbes as delivery vehicles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xycrobe company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Adaptive Phage Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adaptive Phage Therapeutics
2.2 - Growth funds investing in similar companies to Adaptive Phage Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Adaptive Phage Therapeutics
4.2 - Public trading comparable groups for Adaptive Phage Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →